Kinfo
Immunocore Holdings plc ADR logo

Immunocore Holdings plc ADR

IMCRNASDAQHealthcare·US · USD
$29.59
-0.12 (-0.40%)
Prices as of October 5, 2026 · market closed

Price

Key statistics

Valuation
Market cap1.52B USD
Enterprise value1.08B USD
Trailing P/E-41.68
Forward P/E-39.22
PEG ratio0.46
Price / sales3.54
Price / book3.63
Profitability
Gross margin99.06%
Operating margin-2.58%
Profit margin-4.20%
Return on assets-0.16%
Return on equity-4.47%
Income (TTM)
Revenue430.78M USD
Gross profit141.59M USD
EBITDA756.00K USD
Net income-18.07M USD
Diluted EPS-$0.36
Rev. growth (YoY)18.30%
Balance sheet
Total cash880.21M USD
Total debt434.96M USD
Debt / equity103.61
Current ratio4.47
Book value / share$8.16
Cash flow (TTM)
Operating cash flow-34.96M USD
Levered free cash flow35.59M USD
Shares & price
Shares outstanding51.48M
Float45.83M
Held by institutions103.14%
Beta0.82
50-day MA$33.97
200-day MA$32.18
52-week high$40.72
52-week low$27.56
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-060.02-0.02−200.00%2026-05-06-0.260.25+196.15%2026-02-25-0.20-0.60−200.00%2026-01-296.456.57+1.86%2025-11-063.383.39+0.30%
About Immunocore Holdings plc ADR

Immunocore Holdings plc ADR is a commercial-stage biotechnology company focused on developing T cell receptor-based immunotherapies designed to help the immune system recognize and eliminate diseased cells. Immunocore’s lead marketed product, KIMMTRAK, is used to treat unresectable or metastatic uveal melanoma, while its broader platform supports research and development across oncology, infectious diseases, and autoimmune disorders. The company’s ImmTAX technology underpins a portfolio of current and investigational therapies aimed at harnessing or redirecting immune responses with precision. Immunocore serves patients and healthcare providers through specialized therapies that address serious, hard-to-treat conditions, and its programs span clinical development as well as commercial operations in key international markets. Headquartered in Abingdon, United Kingdom, Immunocore Holdings plc ADR remains a notable participant in the biotechnology sector through its focus on novel immune-based medicines.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Bahija Jallal Ph.D.
Employees
524
Headquarters
Abingdon, United Kingdom

Frequently asked questions about Immunocore Holdings plc ADR